Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) will disclose its financial results for Q4 and full-year 2022 on March 28, 2023, at 4:30 PM ET.

The conference call will provide updates on the company's progress in developing AAV-based gene therapies for rare CNS diseases. Participants can join via toll-free and international numbers. Taysha aims to eradicate monogenic CNS diseases by leveraging expertise and a robust gene therapy program.

Positive

• Anticipation of Q4 and full-year 2022 financial results, indicating potential business growth.
• Commitment to developing curative gene therapies for CNS diseases.

Negative

• None.

DALLAS, March 15, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic rare diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2022, and host a corporate update conference call and webcast on Tuesday, March 28, 2023, at 4:30 PM Eastern Time.

Conference Call Details
Tuesday, March 28, at 4:30 PM Eastern Time / 3:30 PM Central Time
Toll Free:	877-407-0792
International:	201-689-8263
Conference ID:	13736479
Webcast:	https://ir.tayshagtx.com/news-events/events-presentations

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:
Carolyn Hawley
Evoke Canale
carolyn.hawley@evokegroup.com

FAQ

When will Taysha Gene Therapies report its financial results?

Taysha Gene Therapies will report its financial results for Q4 and full-year 2022 on March 28, 2023.

What time is the Taysha Gene Therapies conference call scheduled?

The conference call is scheduled for March 28, 2023, at 4:30 PM Eastern Time.

How can I access the Taysha Gene Therapies conference call?

The conference call can be accessed via toll-free number 877-407-0792 or internationally at 201-689-8263.

What is the main focus of Taysha Gene Therapies?

Taysha Gene Therapies focuses on developing AAV-based gene therapies for monogenic rare diseases of the central nervous system.